Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
3.970
+0.150 (3.93%)
At close: Oct 30, 2025, 4:00 PM EDT
4.100
+0.130 (3.27%)
After-hours: Oct 30, 2025, 6:36 PM EDT
Lantern Pharma Employees
Lantern Pharma had 24 employees as of December 31, 2024. The number of employees increased by 3 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
3
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$802,029
Market Cap
42.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 24 | 3 | 14.29% |
| Dec 31, 2023 | 21 | -2 | -8.70% |
| Dec 31, 2022 | 23 | 7 | 43.75% |
| Dec 31, 2021 | 16 | 1 | 6.67% |
| Dec 31, 2020 | 15 | 8 | 114.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LTRN News
- 14 hours ago - Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT - Business Wire
- 2 days ago - Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. - Business Wire
- 6 days ago - Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 - Business Wire
- 6 weeks ago - Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors - Business Wire
- 7 weeks ago - IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN) - GlobeNewsWire
- 2 months ago - Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial - Business Wire
- 2 months ago - Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - Business Wire
- 3 months ago - Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial - Business Wire